Funded by private investors and governments, cancer tests of blood and urine are coming to market.
How much does it cost to bring to market a diagnostic test that’s able to measure cancer without a tissue biopsy?
In the case of Trovagene, almost $100 million.
That’s the cumulative loss, or expense including salaries, R&D, and office space, the money-losing San Diego biotechnology outfit has run up since 1999, when it set out to test for cancer from a cup of urine. Just like recently developed cancer blood tests, the diagnostic the company started offering in May searches for telltale scraps of tumor DNA released by dying cancer cells. The amount of tumor DNA that ends up in urine is a readout, the company says, of whether a tumor has been destroyed or is still growing.
Wall Street analysts expect demand for liquid biopsies to rocket toward $20 billion a year within five years, from about $100 million today.
The idea of such liquid biopsies has leapt to prominence in just the last year. Cancer researchers now expect that the tests will offer a noninvasive way to monitor cancer, find the genetic mutations driving a tumor, or even diagnose it early, before symptoms start. It’s an innovation so big that Wall Street analysts at JP Morgan expect demand for liquid biopsies to rocket toward $20 billion a year within five years, from about $100 million today.
The first DNA blood test for cancer in the United States was commercialized in 2014 by Guardant Health, a venture-backed California company, and tests to spot cancer DNA in blood, urine, or spinal fluid are now in development by a growing number of companies but remain a risky bet for investors.
One pioneering researcher, Dennis Lo, is now tracking more than 20,000 people in Hong Kong to see whether blood screening can catch liver cancer early. Some of his early and ongoing work was paid for by a $1 million grant from the Kadoorie Charitable Foundation, the charity of Hong Kong billionaire Michael Kadoorie, and he later won a $4.25 million award from the Hong Kong government. “It took us about 10 years to convince people to fund us,” he says. Lo says he recently cofounded a company called Cirina to develop blood tests, and he expects initial financing of $12 million from investors.
Investors in the new tests could be disappointed, because while developing a new diagnostic can cost as much as creating a new drug, it’s notoriously hard to make any money off diagnostic tests.
The Latest on: Liquid Biopsy
via Google News
The Latest on: Liquid Biopsy
- Experimental noninvasive tool monitors effectiveness of stem cell transplantation on May 22, 2019 at 4:52 pm
Analysis of the blood test showed responding cells had changed their gene expression, behavior and secretions, suggesting this liquid biopsy could provide a window into stem cell activity and ... […]
- Liquid Biopsy Market Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2019-2026 on May 22, 2019 at 6:28 am
WiseGuyReports.com adds “Liquid Biopsy Market (by Circulating Biomarker, Product, Application, End User, Clinical Application, Cancer Types, Sample Type, Regional & Country Wise Analysis), Initiatives ... […]
- Biopsy Devices Market Growing Developments and Progressions Foreseen by 2022 | By Product Type and Applications Along With Top Key Players on May 21, 2019 at 2:40 pm
This chip is a main component of the VTX-1 system, an automated liquid biopsy platform which provides a simple, label-free isolation of circulating tumor cells directly from a tube of blood. ... […]
- Biocept's stock soars on heavy volume after commercial launch of liquid biopsy test for lung cancer on May 20, 2019 at 12:07 pm
Shares of Biocept Inc. BIOC, +85.38% soared 86% on very heavy volume Monday, after the provider of liquid biopsy tests announced the commercial launch of Target Selector NGS Lung Panel, the liquid ... […]
- Biocept Announces Clinical Validation and Commercial Launch of its Target Selector™ Multi-Gene Liquid Biopsy Panel for Lung Cancer on May 20, 2019 at 8:15 am
Biocept now positioned as the only commercial liquid biopsy provider that offers single-biomarker testing, tumor-specific panels, and circulating tumor cell analysis SAN DIEGO, May 20, 2019 ... […]
- Liquid Biopsy Helps Identify Cancer Patients at Risk of Metastatic Disease on May 16, 2019 at 7:35 pm
In patients with locally advanced rectal cancer, ctDNA a form of liquid biopsy was found to be more accurate technique to monitor treatment response, said The Royal Marsden NHS Foundation Trust ... […]
- Qiagen teams up with Inovio to develop liquid biopsy companion diagnostic on May 16, 2019 at 2:16 pm
QIAGEN N.V. (NYSE:QGEN) will collaborate with Inovio Pharmaceuticals (NASDAQ:INO) to develop a liquid biopsy-based companion diagnostic test aimed at screening patients who would benefit from the ... […]
- New Study Demonstrates Clinical Utility of Liquid Biopsy for Cancer Monitoring on May 15, 2019 at 5:13 am
Researchers from the University Hospital Basel, the University of Porto and the Hospital of Sao Joao looked at matched tissue and liquid biopsies from 159 NSCLC patients. Among 94 of the patients who ... […]
- Grail Sets Fast Pace in Liquid Biopsy with New Milestones on May 13, 2019 at 7:58 am
The Menlo Park, CA-based company has been granted Break Through Device Designation by FDA, in addition, the company will share new data from the Circulating Cell-free Genome Atlas, at ASCO. ... […]
- Grail, the liquid biopsy startup, picks an approach for its cancer test on May 13, 2019 at 7:11 am
Grail, the company that has raised $1.6 billion to develop a blood test to detect cancer early, announced Monday that it has settled on a method for its test and enrolled 115,000 patients in two large ... […]
via Bing News